Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

S Kaye

Showing results (651-660 of 740) with videos related to

Pageof 74
Sort By:
Open Forum Infectious Diseases|December 16, 2020
Assessment of Testing and Treatment of Asymptomatic Bacteriuria Initiated in the Emergency DepartmentLindsay A Petty, Valerie M Vaughn, Scott A Flanders, et al.
Antimicrobial Agents and Chemotherapy|May 7, 2014
Impact of different antimicrobial therapies on clinical and fiscal outcomes of patients with bacteremia due to vancomycin-resistant enterococciKayoko Hayakawa, Emily T Martin, Uma Mahesh Gudur, et al.
The European Respiratory Journal|October 13, 2022
In critically ill patients, anti-anaerobic antibiotics increase risk of adverse clinical outcomesRishi Chanderraj, Jennifer M Baker, Stephen G Kay, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|October 12, 2017
Colistin Versus Ceftazidime-Avibactam in the Treatment of Infections Due to Carbapenem-Resistant EnterobacteriaceaeDavid van Duin, Judith J Lok, Michelle Earley, et al.
British Journal of Cancer|March 20, 2014
A randomised, phase II trial of the DNA-hypomethylating agent 5-aza-2'-deoxycytidine (decitabine) in combination with carboplatin vs carboplatin alone in patients with recurrent, partially platinum-sensitive ovarian cancerR M Glasspool, R Brown, M E Gore, et al.
Infection Control and Hospital Epidemiology|July 16, 2019
Identification of four patients with colistin-resistant Escherichia coli containing the mobile colistin resistance mcr-1 gene from a single health system in MichiganOryan Henig, Laura J Rojas, Michael A Bachman, et al.
The European Respiratory Journal|May 11, 2023
Reply to: Anti-anaerobic antibiotics: indication is keyRishi Chanderraj, Jennifer M Baker, Stephen G Kay, et al.
Antimicrobial Agents and Chemotherapy|May 2, 2012
Impact of cefepime therapy on mortality among patients with bloodstream infections caused by extended-spectrum-β-lactamase-producing Klebsiella pneumoniae and Escherichia coliTeena Chopra, Dror Marchaim, Jennifer Veltman, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|February 1, 2024
Exebacase in Addition to Standard-of-Care Antibiotics for Staphylococcus aureus Bloodstream Infections and Right-Sided Infective Endocarditis: A Phase 3, Superiority-Design, Placebo-Controlled, Randomized Clinical Trial (DISRUPT)Vance G Fowler, Anita F Das, Joy Lipka-Diamond, et al.
Diagnostic Microbiology and Infectious Disease|February 20, 2018
Evaluation of Sensititre Broth Microdilution Plate for determining the susceptibility of carbapenem-resistant Klebsiella pneumoniae to polymyxinsSandra S Richter, James Karichu, Joshua Otiso, et al.
Pageof 74

Showing results (651-660 of 740) with videos related to

Sort By:
Pageof 74
Open Forum Infectious Diseases|December 16, 2020
Assessment of Testing and Treatment of Asymptomatic Bacteriuria Initiated in the Emergency DepartmentLindsay A Petty, Valerie M Vaughn, Scott A Flanders, et al.
Antimicrobial Agents and Chemotherapy|May 7, 2014
Impact of different antimicrobial therapies on clinical and fiscal outcomes of patients with bacteremia due to vancomycin-resistant enterococciKayoko Hayakawa, Emily T Martin, Uma Mahesh Gudur, et al.
The European Respiratory Journal|October 13, 2022
In critically ill patients, anti-anaerobic antibiotics increase risk of adverse clinical outcomesRishi Chanderraj, Jennifer M Baker, Stephen G Kay, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|October 12, 2017
Colistin Versus Ceftazidime-Avibactam in the Treatment of Infections Due to Carbapenem-Resistant EnterobacteriaceaeDavid van Duin, Judith J Lok, Michelle Earley, et al.
British Journal of Cancer|March 20, 2014
A randomised, phase II trial of the DNA-hypomethylating agent 5-aza-2'-deoxycytidine (decitabine) in combination with carboplatin vs carboplatin alone in patients with recurrent, partially platinum-sensitive ovarian cancerR M Glasspool, R Brown, M E Gore, et al.
Infection Control and Hospital Epidemiology|July 16, 2019
Identification of four patients with colistin-resistant Escherichia coli containing the mobile colistin resistance mcr-1 gene from a single health system in MichiganOryan Henig, Laura J Rojas, Michael A Bachman, et al.
The European Respiratory Journal|May 11, 2023
Reply to: Anti-anaerobic antibiotics: indication is keyRishi Chanderraj, Jennifer M Baker, Stephen G Kay, et al.
Antimicrobial Agents and Chemotherapy|May 2, 2012
Impact of cefepime therapy on mortality among patients with bloodstream infections caused by extended-spectrum-β-lactamase-producing Klebsiella pneumoniae and Escherichia coliTeena Chopra, Dror Marchaim, Jennifer Veltman, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|February 1, 2024
Exebacase in Addition to Standard-of-Care Antibiotics for Staphylococcus aureus Bloodstream Infections and Right-Sided Infective Endocarditis: A Phase 3, Superiority-Design, Placebo-Controlled, Randomized Clinical Trial (DISRUPT)Vance G Fowler, Anita F Das, Joy Lipka-Diamond, et al.
Diagnostic Microbiology and Infectious Disease|February 20, 2018
Evaluation of Sensititre Broth Microdilution Plate for determining the susceptibility of carbapenem-resistant Klebsiella pneumoniae to polymyxinsSandra S Richter, James Karichu, Joshua Otiso, et al.
Pageof 74